JP2009540842A5 - - Google Patents

Download PDF

Info

Publication number
JP2009540842A5
JP2009540842A5 JP2009516907A JP2009516907A JP2009540842A5 JP 2009540842 A5 JP2009540842 A5 JP 2009540842A5 JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009540842 A5 JP2009540842 A5 JP 2009540842A5
Authority
JP
Japan
Prior art keywords
seq
mutated
mutant
immunotoxin
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009516907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540842A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2007/050082 external-priority patent/WO2008003327A2/en
Publication of JP2009540842A publication Critical patent/JP2009540842A/ja
Publication of JP2009540842A5 publication Critical patent/JP2009540842A5/ja
Pending legal-status Critical Current

Links

JP2009516907A 2006-07-03 2007-07-03 Cmv感染に関連する疾患の治療のための免疫毒素 Pending JP2009540842A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600900 2006-07-03
PCT/DK2007/050082 WO2008003327A2 (en) 2006-07-03 2007-07-03 Immunotoxins for the treatment of diseases related to cmv infection

Publications (2)

Publication Number Publication Date
JP2009540842A JP2009540842A (ja) 2009-11-26
JP2009540842A5 true JP2009540842A5 (enExample) 2010-08-19

Family

ID=38739380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009516907A Pending JP2009540842A (ja) 2006-07-03 2007-07-03 Cmv感染に関連する疾患の治療のための免疫毒素

Country Status (5)

Country Link
US (1) US8592554B2 (enExample)
EP (1) EP2038302B1 (enExample)
JP (1) JP2009540842A (enExample)
CA (1) CA2656992A1 (enExample)
WO (1) WO2008003327A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN114206944A (zh) * 2019-07-12 2022-03-18 哥本哈根大学 用于治疗cmv感染相关疾病的融合毒素蛋白
US20220324947A1 (en) * 2019-08-05 2022-10-13 Stichting Vu Identification and Elimination of HCMV-Infected Cells
MX2022002628A (es) * 2019-09-03 2022-03-25 Synklino Aps Proteinas de fusion y usos de las mismas.
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白B(gB)多肽

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA2240409C (en) * 1996-01-24 2011-03-22 Schering Corporation Mammalian cx3c chemokine genes
CA2301846A1 (en) * 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
DE69934337T2 (de) 1998-07-22 2007-05-24 Osprey Pharmaceuticals Ltd., Calgary Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
CA2341361A1 (en) * 1998-08-31 2000-03-09 Oregon Health Sciences University Prevention of cell migration initiation with cmv us28 receptor antagonists
EP1272512A4 (en) 2000-03-23 2003-05-07 Phylomed Corp IMMUNOKIN COMPOSITION AND METHOD
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
US20050136033A9 (en) 2002-08-13 2005-06-23 Matthias Mack Method of treating allergen induced airway disease
CN1768862A (zh) * 2004-10-26 2006-05-10 北京诺思兰德生物技术有限责任公司 一类能与表达GnRH受体的癌细胞特异结合且用锝-99m标记的蛋白

Similar Documents

Publication Publication Date Title
TW496870B (en) Compositions methods for stimulating megakaryocyte growth and differentiation
TWI802396B (zh) 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
JP6345216B2 (ja) オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
JP6499333B2 (ja) オキシントモジュリン誘導体を含む高脂血症の治療のための組成物
KR101895047B1 (ko) 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
JP2009540842A5 (enExample)
ES2319827T3 (es) Proteinas quimericas especificas del receptor il-13, y sus usos.
US10188703B2 (en) Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist
TWI423813B (zh) 使用免疫球蛋白片段之長效β干擾素製劑
CN1665933B (zh) 用于治疗肿瘤的免疫缀合物
TWI795443B (zh) Glp-2衍生物之長效接合物
JP2007500236A5 (enExample)
EP3068797A1 (en) Epha3 and multi-valent targeting of tumors
JP2024528496A (ja) ウロキナーゼ型プラスミノーゲン活性化因子受容体関連タンパク質(uparap)を標的とするヒト化抗体を含む、抗体薬物複合体
CN110092837B (zh) Uti融合蛋白
JP2001526242A5 (enExample)
KR101746686B1 (ko) 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체
JP2022513209A (ja) オリゴペプチドを有効成分として含むがんの予防または治療用薬学的組成物
US11752216B2 (en) Insulin analog complex with reduced affinity for insulin receptor and use thereof
JP7668785B2 (ja) 融合タンパク質およびその使用
CN117964777A (zh) 一种接近天然分子的多肽融合分子
WO2010074082A1 (ja) バソヒビン修飾体
CN113329752A (zh) 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法
Nemati et al. The Types and Applications of Peptibodies
RU2024113218A (ru) Конъюгат антитело против cd37-лекарственное средство